ARBUTUS BIOPHARMA CORP NPV financial statements, including revenue, expenses, profit, and loss
The total revenue of 0SGC for the last quarter is 1.34 M USD, and it's 22.42% lower compared to the previous quarter. The net income of Q3 24 is -19.72 M USD.